CD19-rettet kimær antigenreceptor autologe T-celler (CART19) til lupus
CD19-rettet kimær antigenreceptor autologe T-celler (CART19) til unge og unge voksne med systemisk lupus erythematosis (SLE)
This is a single-center, single-arm, open-label phase 1/2 study of CART19 in children and young adults with refractory Systemic lupus erythematosus (SLE), including both patients diagnosed with lupus nephritis (LN) and patients with non-renal Systemic lupus erythematosus (SLE).
Phase 1 will evaluate the safety of CART19 in 6-12 patients with Systemic lupus erythematosus (SLE). There is no planned dose escalation, but a dose de-escalation will be made based on the incidence of Dose Limiting Toxicities. Phase 2 will evaluate the efficacy and further evaluate the safety of CART19 in this population.
Studieoversigt
Status
Status
Betingelser
Betingelser
Intervention / Behandling
Intervention / Behandling
Detaljeret beskrivelse
Lupus disease activity is associated with increased numbers of activated naïve B cells and polyclonal expansion of antibody secreting cells, indicating a central role for B cells in the pathogenesis of SLE. While traditional anti-CD19 antibody therapies have been utilized with varying success in the treatment of Systemic lupus erythematosus (SLE), CD19 directed cellular therapies have emerged as an attractive therapeutic option that may lead to immunosuppression-free remission in this population given the ability of CD19 directed CAR T cells to more deeply deplete the B cell compartment. Previous clinical experience utilizing CD19 directed CAR T cells in patients diagnosed with Systemic lupus erythematosus (SLE) have exceeded any other Systemic lupus erythematosus (SLE) therapeutic available; although, those clinical trials have treated a limited number of subjects. During this trial the test article will be CART19 cells transduced with a lentiviral vector to express anti-CD19 scFv:41-BB:TCRζ, administered by IV injection.
Undersøgelsestype
Undersøgelsestype
Tilmelding (Anslået)
Tilmelding
Fase
Fase
- Fase 2
- Fase 1
Kontakter og lokationer
Studiekontakt
Studiekontakt
- Navn: Caitlin Elgarten, MD
- Telefonnummer: 267-425-7964
- E-mail: elgartenc@chop.edu
Undersøgelse Kontakt Backup
- Navn: Melissa Varghese
- Telefonnummer: 845-553-5358
- E-mail: verghesem@chop.edu
Studiesteder
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Forenede Stater, 19104
- Rekruttering
- Children's Hospital of Philadelphia
-
Kontakt:
- Melissa Varghese
- Telefonnummer: 845-553-5358
- E-mail: varghesem@chop.edu
-
Ledende efterforsker:
- Caitlin Elgarten, MD
-
Kontakt:
- Caitlin Elgarten, MD
- Telefonnummer: 267-425-7964
- E-mail: elgartenc@chop.edu
-
-
Deltagelseskriterier
Berettigelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
-
Signed informed consent form must be obtained prior to any study procedure. Labs or other procedures obtained during routine clinical care may be used for eligibility if obtained within the protocol required window.
-
Patient age must be 10-29 years, inclusive, at time of enrollment.
-
Meeting ACR/EULAR Classification Criteria for SLE
-
ANA positive > 1:80 and/or double-stranded DNA (dsDNA) positive
-
Active (refractory) disease, defined as follows:
a. Lupus nephritis subjects must meet both the following criteria: i. ISN/RPS active nephritis Class III/IV +/- V lupus nephritis diagnosed by biopsy within past 12 months.
ii. Persistent and clinically significant: ≥2 measurements with urine protein with either of the following:
- > 1mg/mg creatinine
- > 0.5 mg/mg creatinine associated with renal dysfunction or low albumin.
- > 0.5 mg/mg creatinine in a patient with rising proteinuria after prior complete renal response b. Non-renal SLE subjects must meet either of the following criteria: i. SLEDAI-2K ≥ 8 and clinical SLEDAI-2K ≥ 6 ii. Inability to decrease prednisone ≤7.5mg/day or 0.15mg/kg/day, whichever is lower, due to active disease.
6. Patients must have had at least 3 months of cumulative conventional therapy defined as:
- Conventional induction immunosuppressive agent(s) (e.g., mycophenolate mofetil, cyclophosphamide), and
- At least one additional therapy:
i. B-cell directed biologic therapy (e.g., rituximab, belimumab, ofatumumab, obinutuzumab) ii. Calcineurin inhibitor (e.g., tacrolimus, cyclosporine, voclosporin) iii. Other immunosuppressive medication for SLE (e.g., anifrolumab, abatacept, JAK inhibitor) 7. Adequate organ function status
-
Renal: eGFR must be ≥30 and subject cannot be receiving dialysis.
-
Hepatic: Transaminases < 5x upper limit of normal and serum conjugated (Direct) bilirubin <1.5x upper limit of normal unless attributable to SLE. If attributable to autoimmune disease, Child-Pugh score must be class A or class B. Child-Pugh score cannot be class C.
-
Cardiac: Shortening fraction > 28%, left ventricular ejection fraction >45%, and no evidence of severe pulmonary hypertension
-
Pulmonary: Must have a minimum level of pulmonary reserve defined as ≤ Grade 1 dyspnea and <Grade 3 hypoxia; DLCO ≥40% (corrected for anemia and/or VA volume if necessary) if PFTs are clinically appropriate as determined by the treating investigator.
8. Subjects of reproductive potential must agree to use acceptable birth control methods.
Exclusion Criteria:
-
Active, untreated infections
-
HIV infection
-
Active Hepatitis B
a. Patients must have a negative hepatitis B surface antigen to be enrolled on this study.
-
Active Hepatitis C
-
Patients with severe neuropsychiatric lupus or neurologic manifestations of SLE (e.g. stroke, seizure, psychosis, demyelinating syndromes, organic brain syndrome, or lupus related headaches)
-
Monogenic lupus (known)
-
Previous autologous or allogenic stem cell transplant
-
Previous kidney transplant
-
History of seizure disorder
-
Patients who are on anti-epileptic therapy
-
Participation in a clinical trial in which the patient receives an investigational drug within a time period equal or less than 5.5 half-lives of the investigational agent prior to study enrollment.
-
Subjects who are unwilling or unable to discontinue immunosuppressive medications at the times of CART19 infusion will be excluded from the trial
-
Any comorbidity that in the opinion of the investigators would jeopardize the ability of the subject to tolerate therapy.
-
Pregnant patients. All participants of childbearing potential must have negative pregnancy test.
-
Lactating participants who want to continue breastfeeding.
-
Patients who are unwilling to consent to LTFU
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: N/A
- Interventionel model: Enkelt gruppeopgave
- Maskning: Ingen (Åben etiket)
Antal våben
Våben og indgreb
Deltagergruppe / ArmDeltagergruppe / Arm |
Intervention / BehandlingIntervention / Behandling |
|---|---|
|
Eksperimentel: CART19
Participants will receive the study product. CART19 cells transduced with a lentiviral vector to express anti-CD19 scFv:41-BB:TCRζ, administered by IV injection. |
CART19 cells transduced with a lentiviral vector to express anti-CD19 scFv:41-BB:TCRζ, administered by IV injection. |
Hvad måler undersøgelsen?
Primære resultatmål
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Frequency of the dose limiting toxicities of CART19
Tidsramme: up to 24 months post infusion
|
Frequency of the dose limiting toxicities of CART19 |
up to 24 months post infusion
|
Sekundære resultatmål
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
2-årig samlet overlevelsesrate
Tidsramme: 24 måneder efter infusion
|
24 måneder efter infusion
|
|
|
2-årig FLARE-fri overlevelsesrate
Tidsramme: Op til 24 måneder efter infusion
|
Op til 24 måneder efter infusion
|
|
|
Rate of childhood SLE Clinical Remission off steroids (cCR-0) within 12 months
Tidsramme: 12 months post treatment
|
12 months post treatment
|
|
|
Feasibility of manufacturing CART19 for participants with SLE
Tidsramme: up to 24 months post infusion
|
Feasibility of manufacturing CART19 measured by the percentage of manufactured products that do not meet release criteria for vector transduction efficiency, T cell product purity, viability, or sterility |
up to 24 months post infusion
|
|
Proportion of patients achieving a complete renal response
Tidsramme: up to 24 months post infusion
|
renal response will be measured by urine protein/creatinine ratio of < 0.5, normal renal function (serum creatinine ≤ULN) without worsening of baseline serum creatinine by more than 15%, and inactive urinary sediment (<10 red blood cells (RBCs)/high-power field (HPF) without RBC casts) |
up to 24 months post infusion
|
|
Proportion of patients achieving a partial renal response
Tidsramme: up to 24 months post infusion
|
partial renal response will be measured by urine protein/creatinine ratio of < 0.5, normal renal function (serum creatinine ≤ULN) without worsening of baseline serum creatinine by more than 15%, and inactive urinary sediment (<10 red blood cells (RBCs)/high-power field (HPF) without RBC casts) |
up to 24 months post infusion
|
|
Rate of CART19 expansion, persistence or B cell aplasia
Tidsramme: up to 24 months post infusion
|
Rate of CART19 expansion, persistence and B cell aplasia will be measured by qPCR and flow cytometry |
up to 24 months post infusion
|
|
Survival of CART19 cells
Tidsramme: up to 24 months post infusion
|
CART19 cell survival will be measured by utilizing polymerase chain reaction analysis of whole blood to detect and quantify number of cells over time. |
up to 24 months post infusion
|
|
Elevations in cytokines in serum
Tidsramme: up to 24 months post infusion
|
to assess bioreactivity and biological response following CART cell infusion, systemic soluble immune and inflammatory factors will be measured by assessing any change in elevations in cytokines in serum prior to infusion and after. |
up to 24 months post infusion
|
Samarbejdspartnere og efterforskere
Sponsor
Sponsor
Efterforskere
Efterforskere
- Ledende efterforsker: Caitlin Elgarten, MD, Children's Hospital of Philadelphia
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Studiestart
Primær færdiggørelse (Anslået)
Primær færdiggørelse
Studieafslutning (Anslået)
Studieafslutning
Datoer for studieregistrering
Først indsendt
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Først opslået
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering sendt
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
- Urogenitale sygdomme
- Mandlige urogenitale sygdomme
- Nyresygdomme
- Urologiske sygdomme
- Urogenitale sygdomme hos kvinder
- Kvinders urogenitale sygdomme og graviditetskomplikationer
- Bindevævssygdomme
- Autoimmune sygdomme
- Sygdomme i immunsystemet
- Glomerulonefritis
- Nefritis
- Hud- og bindevævssygdomme
- Lupus erythematosus, systemisk
- Lupus nefritis
- CTL019 chimært antigenreceptor
Andre undersøgelses-id-numre
Andre undersøgelses-id-numre
- 24-022668
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .